Entrada Therapeutics, Inc.TRDAEarnings & Financial Report
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
Revenue
$37.4M
Gross Profit
N/A
Operating Profit
$-5.9M
Net Profit
$1.1M
Gross Margin
N/A
Operating Margin
-15.7%
Net Margin
3.0%
YoY Growth
-10.6%
EPS
$-0.20
Entrada Therapeutics, Inc. Q4 FY2024 Financial Summary
Entrada Therapeutics, Inc. reported revenue of $37.4M (down 10.6% YoY) for Q4 FY2024, with a net profit of $1.1M (up 111.9% YoY) (3.0% margin).
Key Financial Metrics
| Total Revenue | $37.4M |
|---|---|
| Net Profit | $1.1M |
| Gross Margin | N/A |
| Operating Margin | -15.7% |
| Report Period | Q4 FY2024 |
Entrada Therapeutics, Inc. Annual Revenue by Year
Entrada Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $210.8M).
| Year | Annual Revenue |
|---|---|
| 2024 | $210.8M |
| 2023 | $129.0M |
Entrada Therapeutics, Inc. Quarterly Revenue & Net Profit History
Entrada Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2025 | $20.6M | -65.2% | $-17.3M | -84.4% |
| Q4 FY2024 | $37.4M | -10.6% | $1.1M | 3.0% |
| Q3 FY2024 | $19.6M | -55.3% | $-14.0M | -71.7% |
| Q2 FY2024 | $94.7M | +421.2% | $55.0M | 58.1% |
| Q1 FY2024 | $59.1M | +134.0% | $23.5M | 39.7% |
| Q4 FY2023 | $41.8M | — | $-9.5M | -22.8% |
| Q3 FY2023 | $43.7M | — | $35.5M | 81.1% |
| Q2 FY2023 | $18.2M | — | $-25.9M | -142.7% |
Income Statement
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.2M | $43.7M | $41.8M | $59.1M | $94.7M | $19.6M | $37.4M | $20.6M |
| YoY Growth | N/A | N/A | N/A | 134.0% | 421.2% | -55.3% | -10.6% | -65.2% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $494.0M | $485.0M | $469.2M | $510.8M | $582.0M | $554.6M | $526.3M | $486.5M |
| Liabilities | $287.1M | $238.4M | $226.8M | $241.5M | $152.0M | $132.1M | $97.6M | $69.2M |
| Equity | $206.9M | $246.7M | $242.4M | $269.4M | $429.9M | $422.4M | $428.7M | $417.3M |
Cash Flow
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-35.1M | $-24.5M | $-4.0M | $-25.5M | $39.8M | $-24.3M | $-31.6M | $-38.5M |